Literature DB >> 24203954

Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.

Jiri Bartek1, Martin Mistrik, Jirina Bartkova.   

Abstract

Successful treatment by genotoxic modalities including radiotherapy is commonly hampered by treatment resistance in advanced cancers. Two new studies now reveal that androgen receptor signaling transcriptionally upregulates a large subset of DNA repair genes, thereby enhancing the repair capacity and promoting radioresistance of prostate cancer. These results provide a mechanistic rationale for a combined treatment by ionizing radiation and androgen deprivation therapy. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24203954     DOI： 10.1158/2159-8290.CD-13-0679

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  13 in total

1.  The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

Authors:  L Tosco; A Laenen; A Briganti; P Gontero; R J Karnes; M Albersen; P J Bastian; P Chlosta; F Claessens; F K Chun; W Everaerts; C Gratzke; M Graefen; B Kneitz; G Marchioro; R S Salas; B Tombal; T Van den Broeck; L Moris; A Battaglia; H van der Poel; J Walz; A Bossi; G De Meerleer; K Haustermans; H Van Poppel; M Spahn; S Joniau
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-05-09       Impact factor: 5.554

2.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Authors:  Daniel E Spratt; Michael J Evans; Brian J Davis; Michael G Doran; Man Xia Lee; Neel Shah; John Wongvipat; Kathryn E Carnazza; George G Klee; William Polkinghorn; Donald J Tindall; Jason S Lewis; Charles L Sawyers
Journal:  Cancer Res       Date:  2015-10-02       Impact factor: 12.701

Review 3.  Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Authors:  Gaëtan Devos; Wout Devlies; Gert De Meerleer; Marcella Baldewijns; Thomas Gevaert; Lisa Moris; Daimantas Milonas; Hendrik Van Poppel; Charlien Berghen; Wouter Everaerts; Frank Claessens; Steven Joniau
Journal:  Nat Rev Urol       Date:  2021-09-15       Impact factor: 14.432

Review 4.  Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.

Authors:  Patrick Maier; Linda Hartmann; Frederik Wenz; Carsten Herskind
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

5.  Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation.

Authors:  Pallavi Srivastava; Asitikantha Sarma; Chandra Mohini Chaturvedi
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

Review 6.  Harnessing the potential of multimodal radiotherapy in prostate cancer.

Authors:  Yiannis Philippou; Hanna Sjoberg; Alastair D Lamb; Philip Camilleri; Richard J Bryant
Journal:  Nat Rev Urol       Date:  2020-05-01       Impact factor: 14.432

7.  Advances in prostate cancer research and treatment.

Authors:  Lorenzo Livi; Andrea M Isidori; David Sherris; Giovanni Luca Gravina
Journal:  Biomed Res Int       Date:  2014-08-18       Impact factor: 3.411

8.  Suppression of PC-1/PrLZ sensitizes prostate cancer cells to ionizing radiation by attenuating DNA damage repair and inducing autophagic cell death.

Authors:  Zeng-Fu Shang; Qiang Wei; Lan Yu; Fang Huang; Bei-Bei Xiao; Hongtao Wang; Man Song; Li Wang; Jianguang Zhou; Jian Wang; Shanhu Li
Journal:  Oncotarget       Date:  2016-09-20

9.  Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

Authors:  Lorenzo Tosco; Annouschka Laenen; Thomas Gevaert; Isabelle Salmon; Christine Decaestecker; Elai Davicioni; Christine Buerki; Frank Claessens; Johan Swinnen; Karolien Goffin; Raymond Oyen; Wouter Everaerts; Lisa Moris; Gert De Meerleer; Karin Haustermans; Steven Joniau
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

Review 10.  Targeting DNA Damage Response in Prostate and Breast Cancer.

Authors:  Antje M Wengner; Arne Scholz; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.